

What Has Changed at **Phothera**[®]

Daavlin and National Biological are now Phothera.

Built on the legacy of two trusted phototherapy leaders. Today, it represents the modern continuation of that expertise—focused on improving access to established treatment in clinical practice.

Safety + Guided Treatment

1

Phothera's Guided Mode technology standardizes home NB-UVB phototherapy using guideline-based protocols, built-in safety controls, and step-by-step on-device guidance.

It helps support appropriate dosing and reduces variability in at-home treatment while maintaining physician-directed care.

This enhances consistency, adherence, and safety in delivering proven phototherapy in real-world practice.

Access Evolution

2

Major payer updates from Cigna and Elevance Health/Anthem in 2025 have expanded coverage for home phototherapy, reducing prior restrictions for eligible patients.

And with Phothera Cares, eligible insured patients could pay as little as \$0 out-of-pocket.*

Clinical Evidence

3

Phototherapy remains a foundational treatment in vitiligo care, supported by long-standing clinical use and real-world outcomes.

The Vitiligo Working Group recognizes NB-UVB as a first-line treatment option for generalized vitiligo and an important component of the current standard of care.¹

Additional evidence suggests up to 2x greater repigmentation outcomes when NB-UVB is used in combination versus topical therapy alone.²

New Provider Line

4

As part of our ongoing commitment to our prescribers, we have launched a new provider line for our Phothera customers.

1-844-676-2882

(1-844-67-NBUVB)

- Orders, prior authorization, and shipping status
- Refills and treatment unlocks
- Insurance, coverage, and billing
- Device technical support
- Prescription forms and documentation
- Dosing questions and clinical guidance
- Account setup and operations

* \$0 patient cost applies to eligible insured patients. Not all patients will qualify.

1. Vitiligo Working Group. Mohammad TF et al. J Am Acad Dermatol. 2017;76(5):879–888. 2. Lee et al., JAMA Dermatol. 2019;155(8):929–938

© 2026 Phothera, Inc. All rights reserved.